SOFTWARE Open Access

CHARMS and PROBAST at your fingertips: a template for data extraction and risk of bias assessment in systematic reviews of predictive models

Borja M. Fernandez-Felix^{1,2*}, Jesus López-Alcalde^{1,2,3,4}, Marta Roqué^{2,5}, Alfonso Muriel^{1,2,6} and Javier Zamora^{1,2,7}

Abstract

Background Systematic reviews of studies of clinical prediction models are becoming increasingly abundant in the literature. Data extraction and risk of bias assessment are critical steps in any systematic review. CHARMS and PROBAST are the standard tools used for these steps in these reviews of clinical prediction models.

Results We developed an Excel template for data extraction and risk of bias assessment of clinical prediction models including both recommended tools. The template makes it easier for reviewers to extract data, to assess the risk of bias and applicability, and to produce results tables and figures ready for publication.

Conclusion We hope this template will simplify and standardize the process of conducting a systematic review of prediction models, and promote a better and more comprehensive reporting of these systematic reviews.

Keywords CHARMS, PROBAST, Systematic review, Prognostic model, Template

*Correspondence:

Borja M. Fernandez-Felix

borjamanuel.fernandez@salud.madrid.org

Background

Systematic reviews of clinical prediction model studies are becoming increasingly popular. Prediction models are covered by the type III prognostic research studies proposed by the PROGRESS (PROGnosis RESearch Strategy) partnership [1, 2]. The most common aims of these systematic reviews are to identify and summarize all available models for a particular target population, condition or outcome, and to summarize the predictive performance of a specific prognostic model while identifying potential sources of heterogeneity [3]. During the systematic review process, it is crucial for reviewers to extract key data from the relevant studies. Data extraction provides the reviewer the necessary information for describing and summarizing the findings, and examining the risk of bias and any applicability concerns of the models. Risk of bias refers to the likelihood that a primary predictive model study leads to a distorted, usually



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and the use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativeccommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

¹ Clinical Biostatistics Unit, Hospital Universitario Ramón y Cajal. IRYCIS, Madrid, Spain

² CIBER Epidemiology and Public Health (CIBERESP), Madrid, Spain

³ Institute for Complementary and Integrative Medicine, University Hospital Zurich and University of Zurich, Zurich, Switzerland

⁴ Faculty of Health Sciences, Universidad Francisco de Vitoria (UFV), Madrid, Spain

⁵ Iberoamerican Cochrane Centre - Sant Pau Biomedical Research Institute (IIB-Sant Pau), Barcelona, Spain

⁶ Department of Nursing and Physiotherapy, Universidad de Alcala de Henares, Alcala de Henares, Spain

⁷ Institute of Metabolism and Systems Research, WHO Collaborating Centre for Global Women's Health, University of Birmingham, Birmingham, UK

overly optimistic, estimate of predictive performance. Applicability concerns arise when a primary study question differs from the specific review question in terms of population, predictors or outcomes. Several checklists and toolkits have been developed to guide the process of data extraction and risk of bias assessment for different types of review questions [4].

The CHARMS checklist (CHecklist for critical Appraisal and data extraction for systematic Reviews of prediction Modelling Studies) provides guidance for both formulating the review question, and for extracting data the primary studies reporting prediction models [5].

The PROBAST tool (Prediction model Risk Of Bias Assessment Tool) is a checklist for assessing the risk of bias and the applicability of prognostic model studies [6, 7]. The PROBAST includes four domains: participants, predictors, outcome, and analysis. For each domain the tool provides signalling questions for determining whether the risk of bias and the applicability should be graded as low, high or unclear.

With the aim of facilitating the use of these two tools (i.e. CHARMS and PROBAST) for reviewers performing a systematic review of clinical prediction model studies, we have created an Excel template for extracting data and assessing the risk of bias and the applicability of predictive models.

Implementation

The Excel file (named CHARMS and PROBAST template.xls) consists of eight sheets. The first sheet "Home" provides a description of the Excel file, instructions for its use and links to relevant papers and forms. The following three sheets ("Summary", "CHARMS" and "PROBAST") correspond to the collection of data from the studies included in the systematic review, and the following three sheets ("Study Characteristics", "Model characteristics", and "PROBAST summary") contain the tables and figures generated from the data collected. The final sheet ("CHARMS. Drop-down response lists") allows tailoring of the template to the systematic review. A more detailed description of each sheet is presented next.

To start with the data extraction process, for each predictive model presented in each study included in the systematic review, the user should tick the "new model" box on the "Summary" sheet. This operation enables the CHARMS and PROBAST forms for this new model in the corresponding sheets. The Excel template assumes that each study in the review reports a single prognostic model, but it can easily be

generalized to a study reporting two or more models. In that case, the reviewer shall enable as many rows in the template as models are reported in that study. In the "Summary" sheet the following basic information of the new study should be filled in: author, year, title or an identifier (i.e. PMID or DOI), journal of publication and name of the model, if applicable. An identifier for each model is automatically created based on author name and year. In the last two columns of this summary sheet, the reviewer finds information on the status (i.e. complete or incomplete) of the CHARMS and PROBAST sheets.

The "CHARMS" sheet contains the template from Moons et al. [4]. The data extraction sheet is structured according to the eleven CHARMS domains: source of data, participants, outcome to be predicted, candidate predictors, sample size, missing data, model development, model performance, model evaluation, results and interpretation. To complete the data extraction process reviewers should fill in all the cells shaded in yellow. Depending on the item, the reviewers can choose from a drop-down list of options, or they can enter a free-text response. The items with available drop-down lists are showed in the last sheet of the Excel file (sheet named "CHARMS. Drop-down response lists"). The categories of these default lists can be tailored by the reviewer. When the information in the study report is not available, the reviewer has to fill in the cell with "No information". In the participant description section, reviewers can specify the relevant characteristics that they plan to extract from the primary studies, tailored to the target population in the review. These characteristics will be the same for all models included in the review. For each domain within CHARMS, its status is incomplete whenever a cell within that domain remains empty (marked in yellow). In the observations section of the CHARMS checklist table (bottom part of CHARMS sheet), the reviewer will find a status line that flags each model as "All information has been successfully registered" when all domains are complete, or "Incomplete data extraction" otherwise. Additional information of the model could be extracted and filled in as free text on an additional information field at the bottom line. When all relevant information from a model has been extracted for all domains in the form, the CHARMS checklist for that model is flagged as complete in the "Summary" sheet.

The "PROBAST" sheet contains the template from Wolff et al. [6]. To make information of the model accessible to the reviewers, relevant information

Table 1 Example of CHARMS sheet using data from a primary study included in the systematic review of prognostic models for mortality after cardiac surgery in patients with infective endocarditis [8]

		Gaca, 2011			
0. Study information 0.1 Author		Gaca			
0.2 Publication year		2011			
0.3 Title	Outcomes for endocarditis surgery in North				
0.40.15 - 1 - 1	America: a sin	plified risk scoring system			
0.4 Publication journal 0.5 Model name	J Thor	ac Cardiovasc Surg STSS score			
1. Source of data		5155 score			
1.1 Source of data	F)	kisting registry			
2. Participants					
2.1 Recruitment method	Sel	ective inclusion			
2.2 Recruitment dates		2002 - 2008			
2.3 Study setting		ac surgery centers			
2.4 Study sites (Regions)	N	lorth America			
2.5 Study sites (Number of centers) 2.6 Criteria inclusion	All matiness	Unclear ith the diagnosis of IE who			
2.6 Citteria inclusion	underwent surger	y on the aortic, mitral, and/			
	tr	icuspid valves.			
2.7 Criteria exclusion	gender, status of s endocarditis ty	ed if data were missing on ag urgery, cardiogenic shock, a oe. And if more than 20% of o complication information			
	patients nau n	reported.			
2.8 Participant description	Values	Measures			
2.8.1 Age of participants	55 (46;66)	Median (IQR)			
2.8.2 Native valve endocarditis	No information				
2.8.3 Valve affected	All	Other			
3. Outcome to be predicted	In hospite	d as 20 days as			
3.1 Outcome 3.2 Outcome definition		al or 30 days mortality before discharge or within 3			
J.E Galcome deminion	di	perore discharge or within a sys of surgery.			
3.3 Same outcome definition for all participants		Yes			
3.4 Type of outcome		Single			
3.5 Was the outcome assessed without knowledge of		Unclear			
the predictors? 3.6 Were candidate predictors part of outcome?		No			
3.7 Time of outcome ocurrence	30 days or	lenght of hospital stay			
4. Candidate predictors	Zys 01				
4.1 Number of candidate predictors (or parameters)		38			
assessed					
4.2 Type of predictors		ery and IE related factors			
4.3 Timing of predictors measurement 4.4 Predictors definition and measurement similar for	ļ .	re-operative Yes			
all participants		res			
4.5 Were predictors assessed blinded for outcome?	N	o information			
4.6 Handling of continuous predictors	N	o information			
5. Sample size	~				
5.1 Number of participants		13.617			
5.2 Number of outcomes/events		1.117			
 5.3 Number events per variable (EPV) or per parameter (EPP) 		29,4			
6. Missing data					
6.1 Number of participants with any missing value		98			
6.2 Handling of missing data	N	o information			
7. Model development	Z				
7.1 Modelling method 7.2 Method for selection of candidate predictors		tic GEE regression inivariable associations			
7.3 Method for selection of predictors during		o information			
multivariable modelling					
7.4 Shrinkage of predictor weights or regression		No			
coefficients					
8. Model performance 8.1 Calibration measures	Z	alibration plot			
		Yes			
	No val				
8.1.1 Calibration plot 8.1.2 Calibration slope		ue (95% CI):			
		ue (95% CI): ue (95% CI):			
8.1.2 Calibration slope	No val	ue (95% CI): No			
8.1.2 Calibration slope 8.1.3 Calibration-in-the-large (CITL) 8.1.4 Hosmer-Lemeshow test 8.1.5 Other	No val	ue (95% CI): No Specify:			
8.1.2 Calibration slope 8.1.3 Calibration-in-the-large (CITL) 8.1.4 Hosmer-Lemeshow test 8.1.5 Other 8.2 Discrimination measures	No vali	ue (95% CI): No Specify: C-Statistic			
8.1.2 Calibration slope 8.1.3 Calibration in-the-large (CITL) 8.1.4 Hosemer-lemestow test 8.1.5 Other 8.2 Discrimination measures 8.2.1 C-Statistic	No vali	ue (95% CI): No Specify: C-Statistic ue (95% CI): 0,758			
8.1.2 calibration slope 8.1.3 calibration in the-large (OTL) 8.1.4 Hozmer-Lemeshow test 8.1.5 Other 8.2 Discrimination measures 8.2.1 C-statistic 8.2.2 O-Statistic	No vali	No Specify: C-Statistic ue (95% CI): 0,758 ue (95% CI): 0,758			
8.1.2 Calibration slope 8.1.3 Calibration in-the-large (CITL) 8.1.4 Hosmer-Lemeshow test 8.1.5 Other 8.2 Discrimination measures 8.2.1 C-Statistic 8.2.2 D-Statistic 8.2.3 AUC graph	No val	ue (95% CI): No Specify: C-Statistic ue (95% CI): 0,758 ue (95% CI): No			
8.1.2 calibration slope 8.1.3 calibration in-the-large (OTL) 8.1.4 Hosmer-Lemeshow test 8.1.5 Discrimination measures 8.2.1 C-statistic 8.2.2 D-Statistic 8.3.3 AUC graph 8.4 Log-rank test (if survival analysis)	No vali	No Specify: C-Statistic ue (95% CI): 0,758 ue (95% CI): 0,758			
8.1.2 Calibration slope 8.1.3 Calibration in-the-large (CITL) 8.1.4 Hosmer-Lemeshow test 8.1.5 Other 8.2 Discrimination measures 8.2.1 C-Statistic 8.2.2 D-Statistic 8.2.3 AUC graph	No vali	ue (95% CI): No Specify: C-Statistic ue (95% CI): No No lot applicable			
8.1.2 Calibration slope 8.1.3 Calibration-in-the-large (CITL) 8.1.4 Hosmer-Lemeshow test 8.1.5 Other 8.2 Discrimination measures 8.2.1 C-Statistic 8.2.2 D-Statistic 8.2.2 D-Statistic 8.2.3 AUC graph 8.2.4 Log-rank test (if survival analysis) 8.2.5 Risk group curves (if survival analysis)	No vali	ue (95% CI): No Specify: C-Statistic ue (95% CI): 0,758 ue (95% CI): No lot applicable lot applicable specify: Specify:			
8.1.2 calibration slope 8.1.3 calibration in-the-large (CITL) 8.1.4 Howmer-Lemeshow test 8.1.5 Other 8.2 Discrimination measures 8.2.1 C Statistic 8.2.2 O Statistic 8.2.3 NUZ graph 8.2.4 Log-rank test (if survival analysis) 8.2.5 Risk group curves (if survival analysis) 8.2.5 Other 8.3 Overall measures 8.3.1 R-squared	No vali	ue (95% CI): No Specify: C-Statistic ue (95% CI): 0,758 ue (95% CI): No tot applicable tot applicable Specify: lot evaluated ue (95% CI):			
8.1.2 Calibration slope 8.1.3 Calibration in the large (CITL) 8.1.4 hosmer-Lemeshow test 8.1.5 Other 8.2 Discrimination measures 8.2.1 C-Statistic 8.2.2 D-Statistic 8.2.3 AU graph 8.2.4 Log-rank test (if sunvival analysis) 8.5.5 Risk group curves (if sunvival analysis) 8.2.6 Discrimination services (if sunvival analysis) 8.3.0 Verall measures 8.3.1 Required 8.3.2 Brier score	No vali	ue (95% CI): No No Specify: C-Statistic ue (95% CI): No No tot applicable tot applicable posephy: tot evaluated ue (95% CI): ue (95% CI): ue (95% CI):			
8.1.2 calibration slope 8.1.3 calibration in-the-large (CITL) 8.1.4 Hower-Lemeshow test 8.1.5 Other 8.2 Discrimination measures 8.2.1 C Statistic 8.2.2 D Statistic 8.2.3 NLC graph 8.2.4 Log-rank test (if survival analysis) 8.2.5 Rkg group curves (if survival analysis) 8.2.5 Other 8.3 Overall measures 8.3.1 R-equaved 8.3.2 Refer score 8.3.3 Other	No vali No vali Yes vala No vali No No No vali No vali No vali No vali No vali	ue (95% CI): No Specify: C-Statistic ue (95% CI): No No tot applicable tot applicable tot applicable tot evaluated ue (95% CI): ue (95% CI): Specify: Specify: Specify:			
8.1.2 calibration slope 8.1.3 calibration sin-the-large (CITL) 8.1.4 Hower-Lemeshow test 8.1.5 Other 8.2 Discrimination measures 8.2.1 C-statistic 8.2.2 D-statistic 8.2.3 AU graph 8.2.4 Log-rank test (if survival analysis) 8.5.5 Risk group curves (if survival analysis) 8.5.5 Risk group curves (if survival analysis) 8.2.5 Other 8.3 Overall measures 8.3.1 R-squared 8.2 Brier score 8.3.3 Other 8.4 Clinical utility	No vali No vali Yes vala No vali No No No vali No vali No vali No vali No vali	ue (95% CI): No No Specify: C-Statistic ue (95% CI): No No Iot applicable tot applicable specify: Lot evaluated ue (95% CI): ue (95% CI): ue (95% CI): ue (95% CI): specify: lot devaluated			
8.1.2 Calibration slope 8.1.3 Calibration-in-the-large (CITL) 8.1.4 Hoomer-Lemeshow test 8.1.5 Other 8.2 Discrimination measures 8.2.1 C-Statistic 8.2.2 D-Statistic 8.2.3 AUC graph 9.2.4 Log-rank test (if sun/ival analysis) 8.2.5 Sikk group curves (if sun/ival analysis) 8.2.5 Sikk group curves (if sun/ival analysis) 8.3.6 Other 8.3 Overall measures 8.3.1 Required 8.3.2 Brier score 8.3.3 Other 8.4 Clinical utility 8.4.1 Decision Curve Analysis (DCA)	No vali	ue (95% CI): No Specify: C-Statistic ue (95% CI): No No tot applicable tot applicable tot applicable tot evaluated tot evaluated tot (95% CI): ue (95% CI): ue (95% CI): ue (95% CI): ue (95% CI): tot evaluated No			
8.1.2 calibration slope 8.1.3 calibration in-the-large (OTL) 8.1.4 Howmer-Lemeshow test 8.2.5 Discrimination measures 8.2.1 C-statistic 8.2.2 D-Statistic 8.2.3 AUG graph 8.2.4 Log-rank test (if survival analysis) 8.2.5 Risk group curves (if survival analysis) 8.2.5 Risk group curves (if survival analysis) 8.3.0 verall measures 8.3.0 Results and 8.3.2 Results analysis 8.4.6 Other 8.3.0 Results analysis (DCA) 8.4.1 Decision Curve Analysis (DCA) 8.4.1 Decision Curve Analysis (DCA) 8.4.2 Other	No vali	ue (95% CI): No No Specify: C-Statistic ue (95% CI): No No Iot applicable tot applicable tot applicable ue (95% CI): ue (95% CI): specify: ue (95% CI): ue (95% CI): specify: ue (95% CI): specify: ue (95% CI): specify: ue (95% CI): specify: tot evaluated			
8.1.2 Calibration slope 8.1.3 Calibration in the large (CITL) 8.1.4 Homer-Lemeshow test 8.1.5 Other 8.2 Discrimination measures 8.2.1 C-Statistic 8.2.2 D-Statistic 8.2.2 D-Statistic 8.3.2 AUL graph 8.2.4 Log rank test (if survival analysis) 8.2.5 fisk group curves (if survival analysis) 8.2.6 Other 8.3 Overall measures 8.3.1 R-squared 8.3.2 Brier score 8.3.3 Other 8.4 Clinical utility 8.4.1 Decision Curve Analysis (DCA) 8.4.2 Other	No vali	ue (95% CI): No Specify: C-Statistic ue (95% CI): No No tot applicable tot applicable tot applicable tot evaluated tot evaluated tot (95% CI): ue (95% CI): ue (95% CI): ue (95% CI): ue (95% CI): tot evaluated No			
8.1.2 calibration slope 8.1.3 calibration in-the-large (OTL) 8.1.4 Howmer-Lemeshow test 8.2.5 Discrimination measures 8.2.1 C-statistic 8.2.2 D-Statistic 8.2.3 AUG graph 8.2.4 Log-rank test (if survival analysis) 8.2.5 Risk group curves (if survival analysis) 8.2.5 Risk group curves (if survival analysis) 8.3.0 verall measures 8.3.0 Results and 8.3.2 Results analysis 8.4.6 Other 8.3.0 Results analysis (DCA) 8.4.1 Decision Curve Analysis (DCA) 8.4.1 Decision Curve Analysis (DCA) 8.4.2 Other	No vali No	ue (95% CI): No Specify: C-Statistic ue (95% CI): No No tot applicable tot applicable tot evaluated te (95% CI): ue (95% CI): Specify: tot evaluated No			
8.1.2 calibration slope 8.1.3 calibration in-the-large (CITL) 8.1.4 Hosmor-Lemeshow test 8.1.5 Other 8.2 Discrimination measures 8.2.1 C-Statistic 8.2.2 D-Statistic 8.2.3 AU graph 8.2.4 Log-rank test (if survival analysis) 8.2.5 Risk group curves (if survival analysis) 8.2.5 Risk group curves (if survival analysis) 8.2.5 Other 8.3 Overall measures 8.3.1 Requiered 8.3.2 Parier score 8.3.3 Other 8.4 Clinical utility 8.5.1 Desident ourse Analysis (DCA) 8.6.2 Other 9.1 Method used for testing model performance	No vali No	ue (95% CI): No Specify: C-Statistic ue (95% CI): No No Iot applicable tot applicable Specify: Lot evaluated ue (95% CI): Specify: Lot evaluated No Specify: Specify: Specify: Specify: Specify: Specify: Specify: Specify:			
8.1.2 Calibration slope 8.1.3 Calibration in-the-large (CITL) 8.1.4 hosmer-Lemeshow test 8.1.5 Other 8.2 Discrimination measures 8.2.1 C-Statistic 8.2.2 D-Statistic 8.2.3 AU garank test (if sunvival analysis) 8.2.5 Risk group curves (if sunvival analysis) 8.2.6 Other 8.3 Overall measures 8.3.1 R-quared 8.3.2 Brier score 8.3.3 Other 8.4 Linctia utility 8.4.1 Decision Curve Analysis (DCA) 8.4.1 Decision Curve Analysis (DCA) 9.1 Internal validation 9.1.1 Internal validation 9.1.2 External validation 9.1.2 case of poor validation, whether model was	No vali No	ue (95% CI): No Specify: C-Statistic Le (95% CI): No Le (95% CI): No No Le (95% CI): Specify: Le (95% CI): Le			
8.1.2 calibration slope 8.1.3 calibration in-the-large (CITL) 8.1.4 Hosmor-Lemeshow test 8.1.5 Other 8.2 Discrimination measures 8.2.1 C-Statistic 8.2.2 D-Statistic 8.2.3 AU graph 8.2.4 Log-rank test (if survival analysis) 8.2.5 Risk group curves (if survival analysis) 8.2.5 Risk group curves (if survival analysis) 8.3.5 Risk group curves (if survival analysis) 8.3.0 Event lemesures 8.3.1 Requared 8.3.2 Perier score 8.3.3 Other 8.4 Clinical utility 8.4.1 Desision Curve Analysis (DCA) 8.2 Other 9.1 Method used for testing model performance 9.1.1 Internal validation 9.1 External validation 9.2 In case of poor validation, whether model was adjusted or updated	No vali No	ue (95% CI): No Specify: C-Statistic ue (95% CI): No Not applicable tot applicable tot applicable Specify: Lot evaluated ue (95% CI): ue (95% CI): Specify: Lot evaluated No Specify: Lot ovaluated No Specify: No No Specify: No			
8.1.2 Calibration slope 8.1.3 Calibration-in-the-large (CITL) 8.1.4 Howner-Lemeshow test 8.1.5 Other 8.2 Discrimination measures 8.2.1 C-Statistic 8.2.2 D-Statistic 8.2.3 AU garah 8.2.4 Log-rank test (if survival analysis) 8.5.5 Risk group curves (if survival analysis) 8.2.5 Risk group curves (if survival analysis) 8.2.6 Other 8.3 Overall measures 8.3.1 R-squared 8.3.2 Brier score 8.3.3 Other 8.4 Cother 8.4 Cother 9.1 Method used for testing model performance 9.1.1 Internal validation 9.1.1 Internal validation 9.1.2 External validation 9.2.1 nease of poor validation, whether model was adjusted or updated	No vali No	ue (95% CI): No Specify: C-Statistic ue (95% CI): No			
8.1.2 calibration slope 8.1.3 calibration in-the-large (CITL) 8.1.4 Hosmor-Lemeshow test 8.1.5 Other 8.2 Discrimination measures 8.2.1 C-Statistic 8.2.2 D-Statistic 8.2.3 AU graph 8.2.4 Log-rank test (if survival analysis) 8.2.5 Risk group curves (if survival analysis) 8.2.5 Risk group curves (if survival analysis) 8.3.5 Risk group curves (if survival analysis) 8.3.0 Event analysis 8.3.1 Requared 8.3.2 Perier score 8.3.3 Other 8.4 Clinical utility 8.4.1 Desision Curve Analysis (DCA) 8.4.2 Other 9.1 Method used for testing model performance 9.1.1 Internal validation 9.2 In case of poor validation, whether model was adjusted or updated 10. Results 10.1 Number of predictors (or parameters) included in	No vali No	ue (95% CI): No Specify: C-Statistic ue (95% CI): No Not applicable tot applicable Specify: Lot evaluated ue (95% CI): Lot evaluated No Specify: Lot evaluated No Specify: Lot overwind No Specify: Lot overwind No Specify:			
8.1.2 calibration slope 8.1.3 calibration rische-large (cITL) 8.1.4 Hower-Lemeshow test 8.1.5 Other 8.2 Discrimination measures 8.2.1 C-Statistic 8.2.2 D-Statistic 8.2.3 AU garah 8.2.4 Log-rank test (if survival analysis) 8.2.5 Risk group curves (if survival analysis) 8.2.5 Risk group curves (if survival analysis) 8.2.6 Other 8.3 Overall measures 8.3.1 R-yaquared 8.3.2 Brier score 8.3.3 Other 8.4 Cother 8.4 Clinical utility 8.4.1 Decision Curve Analysis (DCA) 8.4.2 Other 9.1 Internal validation 9.1 In case of poor validation 9.1.1 External validation 9.2.1 case of poor validation, whether model was adjusted or updated 10. Results 10.1 Number of predictors (or parameters) included in final model	No validado No No validado No No Real validado No Real val	ue (95% CI): No Specify: C-Statistic ue (95% CI): No			
8.1.2 callibration slope 8.1.3 callibration in-the-large (CITL) 8.1.4 Howmer-temeshow test 8.1.5 Other 8.2 Discrimination measures 8.2.1 C-Statistic 8.2.2 D-Statistic 8.2.3 NUZ graph 8.2.4 log-rank test (if survival analysis) 8.2.5 Risk group curves (if survival analysis) 8.3.5 Risk group curves (if survival analysis) 8.3.5 Other 8.3 Overall measures 8.3.1 R-squared 8.3.2 Biner score 8.3.3 Other 8.4 Clinical utility 8.4.1 Decision Curve Analysis (DCA) 8.4.2 Other 9.1 Internal validation 9.1.1 Internal validation 9.1.2 External validation 9.1.2 External validation 9.1.2 External validation 10.2 Final model 10.2 Final model included predictor weights or regression coefficients	No validado No No validado No No Real validado No Real val	ue (95% CI): No Specify: C-Statistic ue (95% CI): No			
8.1.2 Calibration slope 8.1.3 Calibration shell-arge (CITL) 8.1.4 Howmer-Lemeshow test 8.1.5 Other 8.2 Discrimination measures 8.2.1.6 Statistic 8.2.2 D-Statistic 8.2.2 D-Statistic 8.3.3 AUC graph 8.2.4 Log-rank test (if survival analysis) 8.2.5 Risk group curves (if survival analysis) 8.2.5 Risk group curves (if survival analysis) 8.3.0 Perall measures 8.3.0 Perall measures 8.3.1 Requared 8.3.2 Brier score 8.3 Deveral measures 8.4 Clinical utility 8.4.1 Decision Curve Analysis (DCA) 8.4.2 Other 9. Model evaluation 9.1 Method used for testing model performance 9.1.1 Internal validation 9.1.2 External validation 9.1.2 External validation 10. Results 10.1.5 Results 10.1.5 Number of predictors (or parameters) included in final model 10.2 Final model included predictor veights or regression coefficients 10.3 Final model included intercept (or baseline	No validado No No validado No No Real validado No Real val	ue (95% CI): No Specify: C-Statistic ue (95% CI): No No No No No No No Ot applicable tot applicable specify: Let (95% CI): Specify: Let (95% CI): Specify: Let (95% CI): Specify: Let waluated No			
8.1.2 calibration slope 8.1.3 calibration in-the-large (CITL) 8.1.4 Howmer-terneshow test 8.1.5 Other 8.2 Discrimination measures 8.2.1 C-Statistic 8.2.2 D-Statistic 8.2.3 LUG graph 8.2.4 Log-rank test (if survival analysis) 8.3.5 Risk group curves (if survival analysis) 8.3.1 Requared 8.3.3 Other 8.4 Clinical utility 8.4.1 Decision Curve Analysis (DCA) 8.4.2 Other 9.1 Method used for testing model performance 9.1.1 Internal validation 9.1 in case of poor validation, whether model was adjusted or updated 10. Results 11.1 Number of predictors (or parameters) included in curve of predictors (or parameters) included in 10.2 Final model 10.2 Final model included predictor weights or regression coefficients 10.3 Final model included intercept (or baseline survival)	No validadi No No validadi No Rai	ue (95% CI): No Specify: C-Statistic ue (95% CI): No No Not applicable tot applicable tot evaluated ue (95% CI): Specify: No			
8.1.2 Calibration slope 8.1.3 Calibration shell-arge (CITL) 8.1.4 Howmer-Lemeshow test 8.1.5 Other 8.2 Discrimination measures 8.2.1.6 Statistic 8.2.2 D-Statistic 8.2.2 D-Statistic 8.3.3 AUC graph 8.2.4 Log-rank test (if survival analysis) 8.2.5 Risk group curves (if survival analysis) 8.2.5 Risk group curves (if survival analysis) 8.3.0 Perall measures 8.3.0 Perall measures 8.3.1 Requared 8.3.2 Brier score 8.3 Deveral measures 8.4 Clinical utility 8.4.1 Decision Curve Analysis (DCA) 8.4.2 Other 9. Model evaluation 9.1 Method used for testing model performance 9.1.1 Internal validation 9.1.2 External validation 9.1.2 External validation 10. Results 10.1.5 Results 10.1.5 Number of predictors (or parameters) included in final model 10.2 Final model included predictor veights or regression coefficients 10.3 Final model included intercept (or baseline	No validadi No No validadi No Rai	ue (95% CI): No Specify: C-Statistic ue (95% CI): No No No No No tot applicable tot applicable stot applicable stot applicable stot valuated ue (95% CI): No			
8.1.2 Calibration slope 8.1.3 Calibration shell-arge (CITL) 8.1.4 Hormer-Lemeshow test 8.1.5 Other 8.2 Discrimination measures 8.2.1 C-Statistic 8.2.2 D-Statistic 8.2.3 D-Statistic 8.3.3 AUG graph 8.2.4 Log-rank test (if survival analysis) 8.5.5 Risk group curves (if survival analysis) 8.5.5 Risk group curves (if survival analysis) 8.1.5 Risk group curves (if survival analysis) 8.2.5 Risk group curves (if survival analysis) 8.3.2 Other 8.3 Overall measures 8.3.1 R-squared 8.3.2 Pirer score 8.3.3 Other 8.4 Chiecia dutity 8.4.1 Decision Curve Analysis (DCA) 8.4.2 Other 9.1 Method used for testing model performance 9.1.1 Internal validation 9.1.1 netural validation 9.1.1 netural validation 9.1.1 netural validation 9.1.1 netural validation 9.1.1 Results 10.1 Falm model included predictor weights or regression coefficients 10.2 Final model included predictor weights or regression coefficients 10.3 Final model included predictor weights or regression coefficients 10.3 Final model included intercept (or baseline survival) 10.4 Atternative presentation of the final prediction models	No valid	ue (95% CI): No Specify: C-Statistic ue (95% CI): No Specify: Specify: Specify: No			
8.1.2 calibration slope 8.1.3 calibration in-the-large (CITL) 8.1.4 Hosmer-Lemeshow test 8.1.5 Other 8.2 Discrimination measures 8.2.1 C-Statistic 8.2.2 D-Statistic 8.2.3 AU tig-rank test (if survival analysis) 8.2.5 Risk group curves (if survival analysis) 8.3.5 Risk group curves (if survival analysis) 8.3.5 Risk group curves (if survival analysis) 8.3.0 Other 8.3 Overall measures 8.3.1 Requared 8.3.2 Discrimination of the survival analysis) 8.4.1 Decision curve Analysis (DCA) 8.4.2 Other 9. Model evaluation 9.1.1 Internal validation 9.1.2 External validation 9.1.1 Internal validation 9.1.1 Internal validation 10.1 Results 10.1 Number of predictors (or parameters) included in final model 11.1 Internal validation or predictors (or parameters) included in final model 10.1 Si Final model included predictor weights or greaters or coefficients 10.3 Final model included predictor weights or greaters or coefficients 10.3 Final model included predictor weights or greaters or coefficients 10.3 Final model included intercept (or baseline survival)	NO validadis No	ue (95% CI): No Specify: C-Statistic ue (95% CI): No No Not applicable tot applicable specify: Let (95% CI): Specify: No			

Abbreviations: Gen General description, App Applicability, RoB Risk of Bias

Table 2 Example of PROBAST sheet using data from a primary study included in the systematic review of prognostic models for mortality after cardiac surgery in patients with infective endocarditis [8]

Domain/ Key questions	Gaca, 2011
0. Study information 0.1 Author	Gaca
0.1 Author 0.2 Publication year	Gaca 2011
0.3 Title	Outcomes for endocarditis surgery in Norti
0.4 Publication journal	America: a simplified risk scoring system
0.4 Publication journal 0.5 Model name	J Thorac Cardiovasc Surg STSS score
1. Participants	212220016
1.1 Were appropriate data sources used?	Probably Yes
1.2 Were all inclusions and exclusions of participants appropriate?	Probably No
Risk of bias introduced by selection of participants	High RoB
Applicability Relevant information extracted from CHARMS:	Low concern
Source of data	Existing registry
Recruitment methods	Selective inclusion
Recruitment dates Study settina	2002 - 2008
Study Setting Inclusion criteria	Cardiac surgery centers All patients with the diagnosis of IE who
	underwent surgery on the aortic, mitral,
Exclusion criteria	and/or tricuspid valves.
EXCUSION CITIENO	Sites were excluded if data were missing or age, gender, status of surgery, cardiogenic
	shock, and endocarditis type. And if more
	than 20% of patients had no complication information reported.
Rationale of bias and applicability rating:	Excluding complete sites if data were
	missing in some variables, likely to have introduced bias but it is less important that
	to exclude individual participants.
2. Predictors	
2.1 Were predictors defined and assessed in a similar way for all participants? 2.2 Were predictor assessments made without knowledge of outcome data?	Yes No Information
2.2 Were predictor assessments made without knowledge or outcome data? 2.3 Are all predictors available at the time the model is intended to be used?	No information Yes
Risk of bias introduced by predictors or their assessment	Low RoB
Applicability	Low concern
Relevant information extracted from CHARMS:	
Predictors definition and measurement similar for all participants Were predictors assessed blinded for outcome?	Yes No information
Timing of predictors measurement	Pre-operative
Rationale of bias and applicability rating:	Excluded complete sites if data were missin
	in some variables, likely to have introduced bias but less important than excluding
	individual participants.
3. Outcome	
3.1 Was the outcome determined appropriately? 3.2 Was a pre-specified or standard outcome definition used?	Yes Yes
3.3 Were predictors excluded from the outcome definition?	Yes
3.4 Was the outcome defined and determined in a similar way for all	Yes
rticipants? 3.5 Was the outcome determined without knowledge of predictor information?	No Information
3.6 Was the ductome determined without knowledge of predictor informations 3.6 Was the time interval between predictor assessment and outcome	Probably Yes
termination appropriate?	
Risk of bias introduced by the outcome or its determination	Low RoB
Applicability Relevant information extracted from CHARMS:	Low concern
Outcome definition	Death occurring before discharge or within
	30 days of surgery. Yes
Same outcome definition for all participants Was the outcome assessed without knowledge of the predictors	res Unclear
Were candidate predictors part of outcome?	No
Time of outcome ocurrence	30 days or lenght of hospital stay
Rationale of bias and applicability rating:	
Analysis Under there a reasonable number of participants with the outcome?	Yes
4.1 Were there a reasonable number of participants with the outcome? 4.2 Were continuous and categorical predictors handled appropriately?	Probably Yes
4.3 Were all enrolled participants included in the analysis?	Probably No
4.4 Were participants with missing data handled appropriately?	Probably No
4.5 Was selection of predictors based on univariable analysis avoided?	No Reshable Year
4.6 Were complexities in the data accounted for appropriately? 4.7 Were relevant model performance measures evaluated appropriately?	Probably Yes Probably No
4.8 Were model overfitting and optimism in model performance accounted for?	No No
4.9 Do predictors and their assigned weights in the final model correspond to	Yes
e results from multivariable analysis?	High RoB
Risk of bias introduced by the analysis Relevant information extracted from CHARMS:	TINGII NOD
Outcome frecuency	1117 from 13617 (8,2%)
Event per variable (EPV) or per parameter (EPP)	29,4
Handling of continuous predictors Number of participants with any missing value	No information
	98 No information
transcer by participants after any missing reads	
китоег ој participants with any missing value Handling of missing data Method for selection of candidate predictors	Based on univariable associations
Handling of missing data	Based on univariable associations Internal: Random split data
Handling of missing data Method for selection of candidate predictors Validation method	Internal: Random split data External: None
Handling of missing data Method for selection of candidate predictors	Internal: Random split data External: None Calibration: Calibration plot
Handling of missing data Method for selection of candidate predictors Validation method	Internal: Random split data External: None Calibration: Calibration plot Discrimination: C-Statistic
Handling of missing data Method for selection of condidate predictors Validation method Performance measures	Internal: Random split data External: None Calibration: Calibration plot Discrimination: C-Statistic Overall: Not evaluated
Handling of missing data Method for selection of candidate predictors Validation method	Internal: Random split data External: None Calibration: Calibration plot Discrimination: C-Statistic
Handling of missing data Method for selection of candidate predictors Validation method Performance measures Shrinkage of predictor weights or regression coefficients	Internal: Random split data External: None Calibration: Calibration plot Discrimination: C-Statistic Overali: Not evaluated No Large EPV (aprox. 30), but predictors selected based on univariable analysis,
Handling of missing data Method for selection of candidate predictors Validation method Performance measures Shrinkage of predictor weights or regression coefficients	Internal: Random split data External: None Calibration: Calibration plot Discrimination: C-Statistic Overall: Not evaluated No Large EPV (aprox. 30), but predictors selected based on univariable analysis, random split sample (D:70% and V:30%)
Handling of missing data Method for selection of candidate predictors Validation method Performance measures Shrinkage of predictor weights or regression coefficients	Internal: Random split data External: None Calibration: Calibration plot Discrimination: C-Statistic Overall: Not evaluated No Large EPV (aprox. 30), but predictors selected based on univariable analysis,

Gray shaded cells are automatically filled based on the information included in the CHARMS sheet

Table 3 Example of the table with study characteristics automatically produced by the Excel file using data from the systematic review of prognostic models for mortality after cardiac surgery in patients with infective endocarditis [8]

Author, Year	Source of data	Enrolment	Study setting	Study region	Participant cha	racteristics	
		period			Age of participants	Native valve endocarditis	Valve affected
Gaca, 2011 [10]	Existing registry	2002—2008	Cardiac surgery centers	North America	55 (46;66)	No information	All
De Feo, 2012 [11]	Retrospective cohort	1980—2009	Cardiac surgery center	Italy	49 (16)	440 (100)	All
Martínez-Sellés, 2014 [12]	Existing registry	2008—2010	Cardiac surgery centers	Spain	61.4 (15.5)	267 (61.1)	All
Madeira, 2016 [13]	Retrospective cohort	2007—2014	Cardiac surgery center	Portugal	60 (47;70)	94 (73.4)	All
Gatti (a), 2017 [14]	Other (specify)	2000—2015 (Italy) 2008 (France)	Cardiac surgery centers	Italy and France	59.1 (15.4)	285 (78.9)	All
Gatti (b), 2017 [14]	Other (specify)	2000—2015 (Italy) 2008 (France)	Cardiac surgery centers	Italy and France	59.1 (15.4)	285 (78.9)	All
Di Mauro, 2017 [15]	Retrospective cohort	2000—2015	Cardiac surgery centers	Italy	59.6 (15.1)	2.221 (82)	All
Gatti (c), 2017 [16]	Retrospective cohort	1999—2015	Cardiac surgery center	Italy	60.6 (8.5)	103 (74.6)	All
Olmos, 2017 [17]	Retrospective cohort	1996—2014	Cardiac surgery centers	Spain	62 (14)	259 (61.1)	Aortic / Mitral
Fernández- Hidalgo (a), 2018 [18]	Retrospective cohort	2000—2011	Cardiac surgery centers	Spain	58 (15.1)	No information	All
Fernández- Hidalgo (b), 2018 [18]	Retrospective cohort	2000—2011	Cardiac surgery centers	Spain	58 (15.1)	No information	All

(such as source of data, inclusion and exclusion criteria, validation methods, performance measures, etc.) from CHARMS domains are automatically transferred into the "PROBAST" sheet. Reviewers should fill in signalling questions for all PROBAST domains: participants, predictors, outcome and analysis. These questions are shaded in yellow and responses should be selected from a drop-down list with the following categories "Yes", "Probably yes", "Probably no", "No" or "No information". Once all signalling questions for one domain have been filled, the risk of bias and applicability assessment cells become editable. Reviewers should rate risk of bias and concerns for applicability of the model as "Low", "High" or "Unclear" for both. When the risk of bias assessment and the applicability of a model have been rated for all domains in the form, the PROBAST assessment for the model is flagged as complete in the "Summary" sheet.

Results

In this section we present a worked example of the template file. This example is based on the data from a systematic review of prognostic models for mortality after cardiac surgery in patients with infective endocarditis [8].

Once we have extracted the data of the models included in the review using the corresponding CHARMS sheet (see Table 1 with data extracted from one of the models as an example) and after completion of the risk of bias assessment using PROBAST sheet (see Table 2 with the risk of bias assessment of the same model), the reviewers could obtain a number of tables and figures aimed to assist in the process of reporting adequately the review findings. All tables and figures can be copied and pasted for further editing.

The first result table automatically created (sheet named: "Study characteristics") shows a summary of the characteristics of included studies listed in

the "Summary" sheet. It presents information covered by methods section (items 4 and 5) and results section (item 13) of the TRIPOD (Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis) statement [9]. The headers of the table include the source of data, the enrolment period, study setting and regions, and the participant characteristics previously predefined in the CHARMS sheet, in our example, these characteristics includes age, specification of native valve endocarditis and valves affected (see Table 3 with characteristics of the studies included in the review).

The second table of results (sheet named: "Model characteristics") shows the relevant information of the

predictive models included in the review. It presents information about the methods section (items 7, 8 and 10) and the results section (item 14) of the TRIPOD statement. In addition, for each included model, a summary of the results of the risk of bias assessment and applicability is shown (see Table 4 with the characteristics of the models reviewed).

The sheet named "PROBAST summary" presents a table and a graph with the results of the risk of bias and applicability assessments (Table 5 and Fig. 1).

The template as well as a filled in file with an example is provided as supplementary material, and this version and further updates can be downloaded from https://github.com/Fernandez-Felix/CHARMS-and-PROBA ST-template.

Table 4 Example of the table with model characteristics automatically produced by the Excel file, using data from the systematic review of prognostic models for mortality after cardiac surgery in patients with infective endocarditis [8]

Author, Year Modelling Sa method s		Events	No pre	dictors	EPV or	Selection of candidate	Selection of final	Number (%) and handling of	Type of	Performance measures			al app				
	method	size	n (%)	Cand.	Final	EPP	predictors	predictors	missng data	validation	Terrormande medsares		Р	Pr	0	Α	
Logistic Gaca, 2011 GEE 13.61		CEE 13 617 I	1117 (8,2)	38	13	29,4	Based on univariable	No information	n (%): 98 (0,7) Method:	Int: Random split data	Cal: Calibration plot Disc : C-Statistic	RoB	-	+	+	_	
	regression		(0,2)				associations	IIIIOIIIIatioii	No information	Ext : None	Ov: Not evaluated	App	+	+	+		
De Feo, 2012	Logistic		Int: None (Apparent	Cal: HL test Disc : C-Statistic / AUC graph	RoB	-	?	+	-								
	regression		(9,1)				associations	information	No information	performance) Ext : None	Ov: Not evaluated	App	-	+	+		
Martínez-Sellés,	Logistic	437	106	Unkown	7	Unknown	Based on univariable	Stepwise	n (%): Unkown Method:	Int: None (Apparent	Cal: HL test Disc : C-Statistic / AUC graph	RoB	+	+	+	-	
2014	regression		(24,3)				associations	selection	on No information performance	performance) Ext : None	Ov: Not evaluated	App	+	+	+		
Madeira, 2016	Logistic	128	21	15	2	1,4	Based on univariable	No	n (%): Unkown Method:	Int: None (Apparent	Cal: Calibration plot / Slope / CITL / HL test	RoB	?	+	+	-	
iviaueira, 2010	regression	120	(16,4)	15	2	1,4	associations	information	No information	performance) Ext : None	Disc : C-Statistic / AUC graph Ov: Brier score	App	?	+	+		
Gatti (a), 2017	Logistic	361	56	57	5	1,0	Based on univariable		Int: Bootstrap Ext :	Cal: HL test Disc : C-Statistic / AUC graph	RoB	+	+	+	-		
Outer (a), 2017	regression	301	(15,5)	3,	9	1,0	associations	elimination	No information		Ov: Not evaluated	App	+	?	+		
Gatti (b), 2017	Logistic	361	56	57	3	1,0	Based on univariable	Backward	n (%): Unkown Method:	Int: Bootstrap Ext : None	Cal: HL test Disc : C-Statistic / AUC graph Ov: Not evaluated	RoB	+	+	+	-	
	regression		(15,5)			-,-	associations	elimination	No information			App	+	+	+		
Di Mauro, 2017	Logistic	2.715	298	32	15	9,3	Based on univariable	No	n (%): Unkown Method:	Int: Bootstrap	Cal: Comparison with the ideal values	RoB	?	+	+	?	
DI Mauro, 2017	regression	2./13	(11,0)	32	13	9,3	associations	information	No information	Ext : None	None Disc : C-Statistic / AUC graph Ov: Brier score	Арр	?	+	+		
0 / \ 0047	Logistic	400	28		_	0.5	Based on	Backward	n (%): 45 (32,6)	Int: Bootstrap Ext : None	Cal: HL test	RoB	+	+	+	-	
Gatti (c), 2017	regression	138	(20,3)	56	5	0,5	univariable associations	elimination	Method: No information		Disc : C-Statistic / AUC graph Ov: Not evaluated	App	+	+	+		
	Logistic		124				Based on univariable	Stepwise	n (%): Unkown	Int: Random split data	Cal: Calibration plot / HL test	RoB	+	+	+	-	
Olmos, 2017	regression	424	(29,2)	37	8	3,4	associations and clinical relevance	selection	Method: No information	Ext : Geographical	Disc : C-Statistic / AUC graph Ov: Not evaluated	Арр	+	+	+		
Fernández-Hidalgo	Logistic	n (%): 4 (0,5) Based on Bootstrap Method: Int-Boo	Int: Bootstrap	Cal: Calibration plot / Slope /	RoB	+	+	+	+								
(a), 2018	regression	779	(26,7)	26	10	8,0	prior knowledge	selection	Complete-case analysis	Ext : None	Disc : C-Statistic / AUC graph Ov: Brier score	Арр	+	?	+		
Fernández-Hidalgo	Logistic	779	208	27	9	7,7	Based on prior	Bootstrap	n (%): 4 (0,5) Method:	Int: Bootstrap	Cal: Calibration plot / Slope / CITL	RoB	+	+	+	+	
(b), 2018	regression	119	(26,7)	21	9	1,1	knowledge	selection	Complete-case analysis	Ext : None	Ext : None	Disc : C-Statistic / AUC graph Ov: Brier score	Арр	+	+	+	

Abbreviations: GEE Generalized Estimating Equation, n: number of event and number of missing data, Cand Number of candidate predictors assessed, EPV Events per variable, EPP Events per parameter, Critical appraisal domains (P Participants, Pr Predictors, O Outcome, A Analysis), Int Internal validation, Ext External validation, Disc Discrimination, Cal Calibration, Ov Overall, CITL Calibration-in-the-large, C: C-Statistic, AUC Area under curve, HL Hosmer–Lemeshow, RoB Risk of Bias, App Applicability

⁺ Low RoB or low corcern for applicability

⁻ High RoB or high concern for applicability

[?] Unclear RoB or applicability

Table 5 Example of the table with the summary of PROBAST tool automatically produced by the Excel file using data from the systematic review of prognostic models for mortality after cardiac surgery in patients with infective endocarditis [8]

Author, Year	Risk of Bias				Applicability		Overall		
	1. Participants	2. Predictors	3. Outcome	4. Analysis	1. Participants	2. Predictors	3. Outcome	Risk of Bias	Applicability
Gaca, 2011 [10]	-	+	+	-	+	+	+	=	+
De Feo, 2012 [11]	-	?	+	-	-	+	+	-	-
Martínez-Sellés, 2014 [12]	+	+	+	-	+	+	+	-	+
Madeira, 2016 [13]	?	+	+	-	?	+	+	=	?
Gatti (a), 2017 [14]	+	+	+	=	+	?	+	=	?
Gatti (b), 2017 [14]	+	+	+	=	+	+	+	=	+
Di Mauro, 2017 [15]	?	+	+	?	?	+	+	?	?
Gatti (c), 2017 [16]	+	+	+	=	+	+	+	=	+
Olmos, 2017 [17]	+	+	+	=	+	+	+	=	+
Fernández- Hidalgo (a), 2018 [18]	+	+	+	+	+	?	+	+	?
Fernández- Hidalgo (b), 2018 [18]	+	+	+	+	+	+	+	+	+

Discussion

We present in this manuscript an Excel template for extracting data and assessing the risk of bias and applicability of predictive modelling studies.

This template is the first to combine the CHARMS and PROBAST tools into one file. The template simplifies and standardizes the tasks of data extraction and risk of bias assessment, reducing the risk of errors and increasing reliability between data extractors. Having the relevant information at hand while assessing the risk of bias will make the review process more efficient. The template is easy to use and allows the reviewers to fill the forms using drop-down lists that are easily customisable. Such customisation makes our template versatile and adaptable to meet users' needs. The template generates several summary tables that can be used directly for publication with minor edits. All these characteristics will speed up the process of performing some of the steps of a systematic review and reporting its findings; surely, systematic reviewers will appreciate its usefulness.

There are some limitations to our template. First, it has been designed to include up to 30 existing models only (or 30 validation studies of a model). Second, the summary tables we produce are generic and might not fit every purpose. However, the tables could be edited outside the template to incorporate other aspects of interest for a specific review.


Conclusion

We have designed a useful template for extracting data and assessing the risk of bias and the applicability of clinical prediction models using the CHARMS and PROBAST checklists. The template makes it easier for reviewers to manage these tools, and to produce results tables ready for publication with minor edits. We hope this template will promote a better and more comprehensive reporting of systematic reviews of prediction models. We encourage piloting the template and providing feedback to improve the template in future versions.

Availability and requirements

Project name: None.

Project home page: None.






Fig. 1 Example of the graph with the summary of PROBAST tool automatically produced by the Excel file using data from the systematic review of prognostic models for mortality after cardiac surgery in patients with infective endocarditis [8]

Operating system(s): Operating system with Microsoft Office

Programming language: Only formulae available in Excel are employed.

Other requirements: None. License: None required.

Any restrictions to use by non-academics: None.

Abbreviations

PROGRESS PROGnosis RESearch Strategy

CHARMS CHecklist for critical Appraisal and data extraction for systematic

Reviews of prediction Modelling Studies

PROBAST Prediction model Risk Of Bias Assessment Tool

TRIPOD Transparent Reporting of a multivariable prediction model for

Individual Prognosis Or Diagnosis

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12874-023-01849-0.

Additional file 1. CHARMS & PROBAST template.

Additional file 2. Example CHARMS and PROBAST template.

Acknowledgements

We are grateful to all members of Clinical Biostatistics Unit at Ramón y Cajal Hospital for their suggestions to improve the template.

Authors' contributions

BMFF contributed to develop the template; the template's validation was done by JZ, AM, JLA, MR; the original draft was written by BMFF and JZ; and all authors contributed to reviewing and editing the article. The authors read and approved the final manuscript.

Fundina

This study has been funded by Instituto de Salud Carlos III through the project PI19/00481, co-funded by European Regional Development Fund "A way to make Europe". BMFF works for and is remunerated by CIBER (Biomedical Research Network in Epidemiology and Public Health). These public funding bodies had no role in the study design, analysis and the interpretation of the results, and the writing of the report nor the decision to submit the paper for publication.

Availability of data and materials

All data generated or analysed during this study are included in this published article [and its supplementary information files].
CHARMS and PROBAST template.xls.

Example CHARMS and PROBAST template.xls.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Received: 7 November 2022 Accepted: 24 January 2023 Published online: 17 February 2023

References

- Croft P, Riley RD, van der Windt DA, Moons KG, Croft P, Riley RD, et al. 22A framework for prognosis research. In: Prognosis Research in Healthcare: Concepts, Methods, and Impact. Oxford University Press; 2019. https://doi.org/10.1093/med/9780198796619.003.0003
- Hemingway H, Croft P, Perel P, Hayden JA, Abrams K, Timmis A, et al. Prognosis research strategy (PROGRESS) 1: a framework for researching clinical outcomes. BMJ. 2013;346:e5595.
- van der Windt DA, Hemingway H, Croft P, Riley RD, Moons KG, Debray TP, et al. 208 Systematic reviews and meta-analysis of prognosis research studies. In: Prognosis Research in Healthcare: Concepts, Methods, and Impact. Oxford University Press; 2019. https://doi.org/10.1093/med/ 9780198796619.003.0010
- Roqué M, Martínez-García L, Solà I, Alonso-Coello P, Bonfill X, Zamora J. Toolkit of methodological resources to conduct systematic reviews. F1000Research. 2020;9:82.
- Moons KGM, de Groot JAH, Bouwmeester W, Vergouwe Y, Mallett S, Altman DG, et al. Critical appraisal and data extraction for systematic reviews of prediction modelling studies: the CHARMS checklist. PLoS Med. 2014;11(10):e1001744.

- Moons KGM, Wolff RF, Riley RD, Whiting PF, Westwood M, Collins GS, et al. PROBAST: a tool to assess risk of bias and applicability of prediction model studies: explanation and elaboration. Ann Intern Med. 2019;170(1):W1.
- Wolff RF, Moons KGM, Riley RD, Whiting PF, Westwood M, Collins GS, et al. PROBAST: a tool to assess the risk of bias and applicability of prediction model studies. Ann Intern Med. 2019;170(1):51.
- Fernandez-Felix BM, Barca LV, Garcia-Esquinas E, Correa-Pérez A, Fernández-Hidalgo N, Muriel A, et al. Prognostic models for mortality after cardiac surgery in patients with infective endocarditis: a systematic review and aggregation of prediction models. Clin Microbiol Infect. 2021;27(10):1422–30.
- Collins GS, Reitsma JB, Altman DG, Moons KGM. Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD). Ann Intern Med. 2015;162(10):735–6.
- 10. Gaca JG, Sheng S, Daneshmand MA, O'Brien S, Rankin JS, Brennan JM, et al. Outcomes for endocarditis surgery in North America: a simplified risk scoring system. J Thor Cardiovasc Surg. 2011;141:98–106.e2.
- De Feo M, Cotrufo M, Carozza A, De Santo LS, Amendolara F, Giordano S, et al. The need for a specific risk prediction system in native valve infective endocarditis surgery. Sci World J. 2012;2012:1–8.
- Martínez-Sellés M, Muñoz P, Arnáiz A, Moreno M, Gálvez J, Rodríguez-Roda J, et al. Valve surgery in active infective endocarditis: a simple score to predict in-hospital prognosis. Int J Cardiol. 2014;175:133–7.
- 13. Madeira S, Rodrigues R, Tralhão A, Santos M, Almeida C, Marques M, et al. Assessment of perioperative mortality risk in patients with infective endocarditis undergoing cardiac surgery: performance of the EuroSCORE I and II logistic models. Interact CardioVasc Thorac Surg. 2016;22:141–8.
- Gatti G, Perrotti A, Obadia J, Duval X, lung B, Alla F, et al. Simple scoring system to predict in-hospital mortality after surgery for infective endocarditis. JAHA. 2017;6(7):e004806.
- Di Mauro M, Dato GMA, Barili F, Gelsomino S, Santè P, Corte AD, et al. A predictive model for early mortality after surgical treatment of heart valve or prosthesis infective endocarditis. The EndoSCORE Int J Cardiol. 2017;241:97–102.
- Gatti G, Benussi B, Gripshi F, Della Mattia A, Proclemer A, Cannatà A, et al. A risk factor analysis for in-hospital mortality after surgery for infective endocarditis and a proposal of a new predictive scoring system. Infection. 2017;45:413–23.
- Olmos C, Vilacosta I, Habib G, Maroto L, Fernández C, López J, et al. Risk score for cardiac surgery in active left-sided infective endocarditis. Heart. 2017;103:1435–42
- Fernández-Hidalgo N, Ferreria-González I, Marsal JR, Ribera A, Aznar ML, de Alarcón A, et al. A pragmatic approach for mortality prediction after surgery in infective endocarditis: optimizing and refining EuroSCORE. Clin Microbiol Infect. 2018;24:1102.e7–15.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.